Therapeutic Antibody Discovery
Pioneering Excellence
30 Years of Antibody Solutions' Innovation
When we launched in 1995, Antibody Solutions staked a global claim as a pioneer in custom antibody discovery services. For nearly three decades we have remained at the forefront of numerous advances in antibody discovery, and this longevity is just one of many reasons why our clients trust us to deliver the therapeutic antibody candidates they need. They might be looking for a specific function, binding to a specific epitope, or a large panel of diverse candidates. We will design our work plan and deploy our collective expertise to ensure the highest likelihood of achieving these objectives so that your project can advance to its next stages.
Strategic, End-to-End Antibody Discovery
Increasingly, clients turn to Antibody Solutions not only for discrete discovery services but instead for expert consultation on developing an integrated, start-to-finish therapeutic antibody discovery program. Why? Because the depth and breadth of our experience means that processes that would challenge many companies are familiar, if not routine, for us.
We always start at the same place – understanding a client’s target, application, and goals. We can then take that understanding to map a project, confident that we have the team, the technology, and the institutional knowledge to navigate through virtually any antibody discovery program.
Designing the Path Your Program Takes
During an initial consultation, we get to know our client’s wants and needs and seek to establish their prospective target and intended application. From there, we can help the client put their best foot forward, advising them on which of the many possible pathways they might pursue.
Clients may come to an initial briefing with certain preconceived discovery strategies in mind. Experience has shown us, perhaps not surprisingly, that different approaches to antibody discovery will deliver different outcomes. Performing target analyses, from our antibody-generation point-of-view, and examining the available antibody-generation pathways may reveal options that lead to more diversity or cost-savings. Without including this analysis of the target for features such as post-translational modifications, structural complexity, and species homology, the chances that any immunization strategy will succeed are reduced.
Our client may also expect the successful lead candidate to have certain characteristics such as binding or blocking. Knowing this up-front saves time and expense over the course of the program by allowing us to design a bespoke screening cascade upfront. This allows us to eliminate undesirable or irrelevent candidates earlier in the process.
Generating Your Lead Therapeutic Candidate
Developing a therapeutic that is effective and can pass FDA muster (multiple hurdles) is a hard process. You want to start with a panel of great candidates.
Use Cellestive and let us help guide you.
There are lots of choices out there, let us present you with the options and you decide how to proceed.
Don’t forget about Transgenic Animal Options.
Have you thought about them?
Are you considering alternative modalities
No matter the therapeutic modality, a quality lead matters
Getting Started with Your Therapeutic Discovery Program
Armed with the clients lead candidate profile, we’re ready to develop a comprehensive proposal for the program. This typically includes:
-
Target Analysis
-
Antigen Development
-
Immunization Strategy
-
Multiple Screening at Critical Points
-
Discovery Services of Our Hybridoma Library Primary B-Cell or Guided NGS
Contact Us to Kickstart a Proposal Process that’s Cued to Our Most Important End Goal: Yours.
Related Resources
1 min read
Pathways to Antibody Discovery Using the Cellestive™ Platform
Cellestive™ leverages the success of immune rodents in raising diverse and devel...
1 min read
Generation Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery
"Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery” de...
1 min read
Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse
Immunization of transgenic animals producing human antibodies is by far the most...